PARP1 expression in soft tissue sarcomas is a poor-prognosis factor and a new potential therapeutic target.

Mol Oncol · 2019 · PMC6599836 · PMID 31131495

Europe PMC DOI

hedged sentence

0.0670

closest p · 1.3× alpha

0.0670

boldest claim

The sentences

showed a trendP = 0.067so close (0.05 < p ≤ 0.1)

The analysis of MFS in the 345 chemotherapy‐untreated cases showed a trend ( P = 0.067, log‐rank test) for longer MFS in the ‘PARP1‐low’ class (71% 5‐year MFS, 95% CI: 64–78) than in the ‘PARP1‐high’ class (60% 5‐year MFS, 95% CI: 50–73).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.